![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PLCB1 |
Gene summary for PLCB1 |
![]() |
Gene information | Species | Human | Gene symbol | PLCB1 | Gene ID | 23236 |
Gene name | phospholipase C beta 1 | |
Gene Alias | DEE12 | |
Cytomap | 20p12.3 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q9NQ66 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
23236 | PLCB1 | CCI_3 | Human | Cervix | CC | 3.51e-23 | 1.15e+00 | 0.516 |
23236 | PLCB1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 4.27e-06 | -3.11e-01 | 0.0155 |
23236 | PLCB1 | HTA11_2487_2000001011 | Human | Colorectum | SER | 7.02e-04 | -4.51e-01 | -0.1808 |
23236 | PLCB1 | HTA11_78_2000001011 | Human | Colorectum | AD | 1.07e-02 | -3.80e-01 | -0.1088 |
23236 | PLCB1 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.29e-09 | -4.72e-01 | -0.1954 |
23236 | PLCB1 | HTA11_866_2000001011 | Human | Colorectum | AD | 6.44e-08 | -3.34e-01 | -0.1001 |
23236 | PLCB1 | HTA11_1391_2000001011 | Human | Colorectum | AD | 2.93e-03 | -2.88e-01 | -0.059 |
23236 | PLCB1 | HTA11_7862_2000001011 | Human | Colorectum | AD | 2.11e-02 | -5.64e-01 | -0.0179 |
23236 | PLCB1 | HTA11_10711_2000001011 | Human | Colorectum | AD | 1.98e-04 | -4.91e-01 | 0.0338 |
23236 | PLCB1 | HTA11_7696_3000711011 | Human | Colorectum | AD | 2.38e-06 | -4.41e-01 | 0.0674 |
23236 | PLCB1 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.35e-12 | -5.25e-01 | 0.294 |
23236 | PLCB1 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 6.60e-07 | -3.80e-01 | 0.3859 |
23236 | PLCB1 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 5.95e-03 | -5.37e-01 | 0.2585 |
23236 | PLCB1 | A001-C-207 | Human | Colorectum | FAP | 1.11e-10 | -5.25e-01 | 0.1278 |
23236 | PLCB1 | A015-C-203 | Human | Colorectum | FAP | 4.26e-15 | -5.28e-01 | -0.1294 |
23236 | PLCB1 | A015-C-204 | Human | Colorectum | FAP | 1.52e-02 | -3.79e-01 | -0.0228 |
23236 | PLCB1 | A002-C-201 | Human | Colorectum | FAP | 1.69e-10 | -4.77e-01 | 0.0324 |
23236 | PLCB1 | A002-C-203 | Human | Colorectum | FAP | 3.58e-03 | -3.70e-01 | 0.2786 |
23236 | PLCB1 | A001-C-108 | Human | Colorectum | FAP | 6.39e-08 | -4.00e-01 | -0.0272 |
23236 | PLCB1 | A002-C-021 | Human | Colorectum | FAP | 6.74e-03 | -3.54e-01 | 0.1171 |
Page: 1 2 3 4 5 6 7 8 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00026837 | Cervix | CC | negative regulation of immune system process | 94/2311 | 434/18723 | 2.63e-08 | 1.87e-06 | 94 |
GO:00975298 | Cervix | CC | myeloid leukocyte migration | 56/2311 | 220/18723 | 7.21e-08 | 4.15e-06 | 56 |
GO:00447725 | Cervix | CC | mitotic cell cycle phase transition | 89/2311 | 424/18723 | 2.70e-07 | 1.12e-05 | 89 |
GO:00018197 | Cervix | CC | positive regulation of cytokine production | 95/2311 | 467/18723 | 4.88e-07 | 1.85e-05 | 95 |
GO:00310988 | Cervix | CC | stress-activated protein kinase signaling cascade | 58/2311 | 247/18723 | 8.02e-07 | 2.89e-05 | 58 |
GO:00509007 | Cervix | CC | leukocyte migration | 78/2311 | 369/18723 | 1.09e-06 | 3.80e-05 | 78 |
GO:00026857 | Cervix | CC | regulation of leukocyte migration | 50/2311 | 210/18723 | 2.95e-06 | 8.31e-05 | 50 |
GO:00514038 | Cervix | CC | stress-activated MAPK cascade | 55/2311 | 239/18723 | 2.96e-06 | 8.31e-05 | 55 |
GO:00454445 | Cervix | CC | fat cell differentiation | 53/2311 | 229/18723 | 3.72e-06 | 9.75e-05 | 53 |
GO:20000453 | Cervix | CC | regulation of G1/S transition of mitotic cell cycle | 37/2311 | 142/18723 | 6.33e-06 | 1.53e-04 | 37 |
GO:00457876 | Cervix | CC | positive regulation of cell cycle | 66/2311 | 313/18723 | 7.78e-06 | 1.81e-04 | 66 |
GO:00703027 | Cervix | CC | regulation of stress-activated protein kinase signaling cascade | 46/2311 | 195/18723 | 9.35e-06 | 2.11e-04 | 46 |
GO:00000824 | Cervix | CC | G1/S transition of mitotic cell cycle | 49/2311 | 214/18723 | 1.16e-05 | 2.48e-04 | 49 |
GO:19028062 | Cervix | CC | regulation of cell cycle G1/S phase transition | 41/2311 | 168/18723 | 1.18e-05 | 2.51e-04 | 41 |
GO:00073466 | Cervix | CC | regulation of mitotic cell cycle | 88/2311 | 457/18723 | 1.26e-05 | 2.60e-04 | 88 |
GO:19019903 | Cervix | CC | regulation of mitotic cell cycle phase transition | 63/2311 | 299/18723 | 1.27e-05 | 2.60e-04 | 63 |
GO:00716755 | Cervix | CC | regulation of mononuclear cell migration | 31/2311 | 115/18723 | 1.67e-05 | 3.22e-04 | 31 |
GO:00448434 | Cervix | CC | cell cycle G1/S phase transition | 53/2311 | 241/18723 | 1.76e-05 | 3.32e-04 | 53 |
GO:00459316 | Cervix | CC | positive regulation of mitotic cell cycle | 32/2311 | 121/18723 | 1.88e-05 | 3.47e-04 | 32 |
GO:00512713 | Cervix | CC | negative regulation of cellular component movement | 73/2311 | 367/18723 | 2.22e-05 | 3.95e-04 | 73 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0541520 | Cervix | CC | Diabetic cardiomyopathy | 76/1267 | 203/8465 | 1.40e-15 | 6.46e-14 | 3.82e-14 | 76 |
hsa0501018 | Cervix | CC | Alzheimer disease | 113/1267 | 384/8465 | 9.67e-14 | 3.92e-12 | 2.32e-12 | 113 |
hsa0501618 | Cervix | CC | Huntington disease | 94/1267 | 306/8465 | 8.49e-13 | 3.06e-11 | 1.81e-11 | 94 |
hsa0502218 | Cervix | CC | Pathways of neurodegeneration - multiple diseases | 128/1267 | 476/8465 | 2.87e-12 | 9.29e-11 | 5.50e-11 | 128 |
hsa0541720 | Cervix | CC | Lipid and atherosclerosis | 65/1267 | 215/8465 | 6.47e-09 | 1.10e-07 | 6.52e-08 | 65 |
hsa0516318 | Cervix | CC | Human cytomegalovirus infection | 65/1267 | 225/8465 | 4.59e-08 | 6.47e-07 | 3.83e-07 | 65 |
hsa0513120 | Cervix | CC | Shigellosis | 69/1267 | 247/8465 | 7.64e-08 | 1.03e-06 | 6.10e-07 | 69 |
hsa0491520 | Cervix | CC | Estrogen signaling pathway | 44/1267 | 138/8465 | 3.55e-07 | 3.97e-06 | 2.35e-06 | 44 |
hsa0472318 | Cervix | CC | Retrograde endocannabinoid signaling | 42/1267 | 148/8465 | 1.79e-05 | 1.42e-04 | 8.40e-05 | 42 |
hsa043109 | Cervix | CC | Wnt signaling pathway | 43/1267 | 171/8465 | 3.03e-04 | 1.64e-03 | 9.68e-04 | 43 |
hsa051465 | Cervix | CC | Amoebiasis | 29/1267 | 102/8465 | 3.31e-04 | 1.70e-03 | 1.01e-03 | 29 |
hsa0491212 | Cervix | CC | GnRH signaling pathway | 26/1267 | 93/8465 | 8.72e-04 | 3.87e-03 | 2.29e-03 | 26 |
hsa0501716 | Cervix | CC | Spinocerebellar ataxia | 35/1267 | 143/8465 | 1.77e-03 | 7.21e-03 | 4.26e-03 | 35 |
hsa0492812 | Cervix | CC | Parathyroid hormone synthesis, secretion and action | 27/1267 | 106/8465 | 3.12e-03 | 1.19e-02 | 7.03e-03 | 27 |
hsa04062 | Cervix | CC | Chemokine signaling pathway | 43/1267 | 192/8465 | 3.60e-03 | 1.34e-02 | 7.91e-03 | 43 |
hsa049336 | Cervix | CC | AGE-RAGE signaling pathway in diabetic complications | 25/1267 | 100/8465 | 5.64e-03 | 1.88e-02 | 1.11e-02 | 25 |
hsa046213 | Cervix | CC | NOD-like receptor signaling pathway | 41/1267 | 186/8465 | 5.90e-03 | 1.95e-02 | 1.15e-02 | 41 |
hsa0497116 | Cervix | CC | Gastric acid secretion | 20/1267 | 76/8465 | 6.93e-03 | 2.27e-02 | 1.34e-02 | 20 |
hsa049265 | Cervix | CC | Relaxin signaling pathway | 30/1267 | 129/8465 | 7.92e-03 | 2.56e-02 | 1.51e-02 | 30 |
hsa049218 | Cervix | CC | Oxytocin signaling pathway | 34/1267 | 154/8465 | 1.12e-02 | 3.42e-02 | 2.02e-02 | 34 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PLCB1 | SNV | Missense_Mutation | rs142186851 | c.502N>T | p.Arg168Cys | p.R168C | Q9NQ66 | protein_coding | deleterious(0.03) | benign(0.097) | TCGA-BR-8372-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Chemotherapy | etoposide | CR |
PLCB1 | SNV | Missense_Mutation | c.308N>A | p.Ile103Asn | p.I103N | Q9NQ66 | protein_coding | deleterious(0) | benign(0.124) | TCGA-CD-A4MG-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
PLCB1 | SNV | Missense_Mutation | rs868772684 | c.301C>T | p.Arg101Cys | p.R101C | Q9NQ66 | protein_coding | deleterious(0) | benign(0.014) | TCGA-CG-4306-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
PLCB1 | SNV | Missense_Mutation | c.3011A>C | p.Lys1004Thr | p.K1004T | Q9NQ66 | protein_coding | deleterious(0.04) | possibly_damaging(0.597) | TCGA-D7-6822-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
PLCB1 | SNV | Missense_Mutation | c.1012N>A | p.Gly338Ser | p.G338S | Q9NQ66 | protein_coding | deleterious(0.03) | possibly_damaging(0.841) | TCGA-HU-A4GU-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
PLCB1 | SNV | Missense_Mutation | c.1274N>T | p.Ala425Val | p.A425V | Q9NQ66 | protein_coding | deleterious(0) | probably_damaging(0.937) | TCGA-HU-A4GU-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
PLCB1 | SNV | Missense_Mutation | novel | c.2078N>C | p.Val693Ala | p.V693A | Q9NQ66 | protein_coding | deleterious(0.03) | possibly_damaging(0.687) | TCGA-VQ-A8P2-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unspecific | Complete Response | |
PLCB1 | deletion | Frame_Shift_Del | c.2911delN | p.Lys972ArgfsTer30 | p.K972Rfs*30 | Q9NQ66 | protein_coding | TCGA-B7-5816-01 | Stomach | stomach adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |||
PLCB1 | insertion | Frame_Shift_Ins | novel | c.3185_3186insTG | p.Glu1062AspfsTer8 | p.E1062Dfs*8 | Q9NQ66 | protein_coding | TCGA-BR-8486-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
PLCB1 | deletion | Frame_Shift_Del | novel | c.1561delN | p.Lys522AsnfsTer23 | p.K522Nfs*23 | Q9NQ66 | protein_coding | TCGA-CG-4442-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
23236 | PLCB1 | ENZYME, DRUGGABLE GENOME, PHOSPHOLIPASE | Selective serotonin reuptake inhibitors | 25649181 |
Page: 1 |